Aspen China was incorporated as a wholly foreign-owned enterprise in July 2015 but has not been a significant contributor to the Group performance prior to the 2017 financial year. China is set to become a material contributor to Group revenue with a product range comprising the recently acquired thrombosis and anaesthetic brands as well as some smaller global brands.
Contribution to Group revenue
Revenue contribution - by therapeutic category
- China made up 37% of the total Asian pharmaceutical sector with an estimated value of USD80 billion as at 30 December 2016.
- Over the same period, the China pharmaceutical sector grew 7,9% in local currency, mostly driven by the 8,4% growth in prescription medication usage in hospitals.
Source: June 2017 IMS
Number of products launched:
Number of product recalls:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2017||2016 (CER)*||% change|
* Constant exchange rate: FY16 restated at FY17 average exchange rates. Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.